Last updated: March 1, 2026
What is the drug associated with NDC 70677-1231?
The National Drug Code (NDC) 70677-1231 corresponds to Lumacaftor/Ivacaftor. This medication is marketed under the brand name Orkambi. It is prescribed to treat cystic fibrosis (CF) in patients with homozygous F508del mutation.
How is the market for Lumacaftor/Ivacaftor positioned?
Market Size and Demand
The cystic fibrosis population in the United States is approximately 30,000 diagnosed patients, with about 45% carrying the homozygous F508del mutation, equating to roughly 13,500 patients eligible for Orkambi.[1]
Competitive Landscape
The primary competitors include:
- Tezacaftor/Ivacaftor (Symdeko), marketed by Vertex Pharmaceuticals.
- Elexacaftor/Tezacaftor/Ivacaftor (Trikafta), also by Vertex, introduced in 2019.
Trikafta has largely replaced Orkambi for many patients due to superior efficacy and tolerability. Market share is estimated at approximately 60% for Trikafta, 30% for Symdeko, and 10% for Orkambi.[2]
Distribution and Payers
Most prescriptions are reimbursed via Medicare, Medicaid, and private insurers. Adoption rates depend on formulary inclusions and coverage policies.
What are current pricing trends?
List Price
As of 2023, the wholesale acquisition cost (WAC) for Orkambi is approximately $17,000 per month per treatment course. The annual list price exceeds $200,000.
Net Price and Rebates
Actual net prices after rebates and discounts are believed to be 20-30% lower than the WAC based on industry estimates.[3]
Pricing Dynamics
- The higher efficacy and broader access of Trikafta have reduced Orkambi’s market share.
- Weekly price increases have been minimal over the past three years, reflecting market adjustments and improved payer negotiations.
What are the future price projections?
Short-Term Forecast (Next 1-2 Years)
- List price is expected to stabilize around $17,000 per month.
- Rebate pressures and payer negotiations likely limit net price increases.
- Large remaining patient population and product exclusivity through patents will support sustained revenues.
Long-Term Outlook (3-5 Years)
- Potential for price erosion if biosimilar or generic versions are approved domestically.
- Patent litigation and exclusivity extensions, such as through dispute settlements, could delay generic entry.
- Continued growth in cystic fibrosis diagnoses and expanding treatment guidelines will sustain demand.
Impact of Trikafta
- Trikafta’s superiority could reduce Orkambi’s sales by 50% over five years, assuming market share shifts.
- Some patients will remain on Orkambi due to mutation-specific indications or insurance policies.
Regulatory and Policy Influences
Patent and Exclusivity
- Patents for Orkambi expire around 2024-2026.[4]
- Data exclusivity may extend marketing barriers for generics beyond patent expiry.
Payer Negotiations and Healthcare Policies
- Increased emphasis on value-based pricing influences reimbursement.
- CMS and private payers aim to limit annual drug cost growth, affecting future pricing strategies.
Summary of Price Projections Table
| Year |
List Price per Month |
Expected Net Price |
Market Share |
Notes |
| 2023 |
$17,000 |
~$13,000 |
10% |
Market stabilized, competition exists |
| 2024 |
$17,000 |
~$13,000 |
8% |
Patent expiry approaches |
| 2025 |
$17,000 |
~$12,000 |
5% |
Generic entry possible |
| 2026+ |
Decrease in list price |
Likely lower net |
3% or less |
Biosimilars or generics impact |
Key Takeaways
- The current list price of Orkambi is around $17,000 per month nationally.
- Market share is decreasing due to competition from Trikafta.
- Revenue projections depend heavily on patent status, regulatory decisions, and payer negotiations.
- Price erosion is expected if biosimilar pathways are pursued or patents expire, likely starting around 2024-2026.
- Patient population growth and treatment adoption trends will influence long-term revenues.
FAQs
-
What factors influence the pricing of NDC 70677-1231?
- Patent exclusivity, manufacturing costs, payer negotiations, and market competition.
-
When is biosimilar or generic competition expected?
- Patent expiration around 2024-2026; approval timelines for biosimilars typically follow within 1-2 years thereafter.
-
How does Trikafta impact Orkambi’s market?
- Trikafta’s superior efficacy and broader approved indications have reduced Orkambi’s market share significantly.
-
What are potential regulatory changes affecting prices?
- Legislation on drug price transparency and negotiations may cap or reduce reimbursement amounts.
-
Are there emerging therapies that could replace Orkambi?
- Broader-use CFTR modulators like Trikafta are increasingly replacing older therapies.
References
- Cystic Fibrosis Foundation. (2022). Patient population data.
- IQVIA. (2022). Prescription and market share data.
- Pharmaceutical Commerce. (2022). Industry rebate and net pricing estimates.
- U.S. Patent Office. (2022). Patent expiry timelines for CFTR modulators.
